US4724148A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Amosulalol hydrochloride long acting formulation
Assignee: Astellas Pharma Inc
•
Filing: 1986-11-14
•
Granted: 1988-02-09
•
Expires: 2006-11-14
Abstract
Abstract Long acting formulations of amosulalol hydrochloride are provided, wherein the frequency of administering the hypotensive agent is minimized and wherein such formulations are prepared by compounding amosulalol hydrochloride with an enterosoluble material and optionally the inclusion of an organic acid.
Inventors
- 👤 Takashi Sonobe
- 👤 Hiroshi Sugiura
- 👤 Tomoh Itoh
- 👤 Masayoshi Aruga
- 👤 Hiroitsu Kawata
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 08:12
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1635; A61K31/00; A61K31/16; A61K31/18; A61K9/1617; A61K9/1652; A61K9/2095; A61P; A61P25/00; A61P25/02; A61P9/00; A61P9/12
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
76 words
A long acting pharmaceutical formulation comprising a pharmaceutically effective amount of amosulalol hydrochloride, from about 5 to about 50 weight percent of said formulation of an entero-soluble material selected from the group consisting of a methacrylic acid-ethyl acrylate copolymer, a methacrylic acid-methyl methacrylate copolymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate and shellac, from about 1 to about 30 weight percent of a pharmaceutically acceptable organic acid, and the balance being at least one pharmaceutically acceptable additive.
Claim 2
Dependent Claim
76 words
A long acting pharmaceutical formulation comprising a pharmaceutically effective amount of amosulalol hydrochloride, from about 5 to about 50 weight percent of said formulation of an entero-soluble material selected from the group consisting of a methacrylic acid-ethyl acrylate copolymer, a methacrylic acid-methyl methacrylate copolymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate and shellac, from about 1 to about 30 weight percent of a pharmaceutically acceptable organic acid, and the balance being at least one pharmaceutically acceptable additive.
Claim 3
Dependent Claim
29 words
A method for the treatment of a subject afflicted with hypertension which comprises administering to said subject an antihypertensive effective amount of the long acting formulation of claim 1.
Claim 4
Dependent Claim
12 words
The method of claim 2 wherein the entero-soluble material is hydroxypropylmethylcellulose phthalate.
Claim 5
Dependent Claim
18 words
The method of claim 2 wherein the entero-soluble material is hydroxypropylmethylcellulose phthalate and the organic acid is citric
References Cited (Backward Citations)
US3520970A
Cited
US3538214A
Cited
US3835221A
Cited
US3775537A
Cited
US3954959A
Cited
US4083949A
Cited
US4361546A
Cited
US4289750A
Cited
US4367217A
Cited
US4427648A
Cited
US4438091A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-02-08 | 1991-08-10 | 1992-02-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-02-08 | 1995-08-10 | 1996-02-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-02-08 | 1999-08-10 | 2000-02-09 | $7700.00 | Window Closed / Lapsed |